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Summary terized by severe recurrent nosebleeds, mucocutaneous
telangiectases, gastrointestinal hemorrhage, and a highThe activin receptor–like kinase 1 gene (ALK-1) is the
incidence of vascular malformations in the lung andsecond locus for the autosomal dominant vascular dis-
brain (Guttmacher et al. 1995). Most of the publishedease hereditary hemorrhagic telangiectasia (HHT). In
families with HHT fall into two linkage groups: HHT1,this paper we present the genomic structure of the ALK-
mapping to chromosome 9q33 (McDonald et al. 1994;1 gene, a type I serine-threonine kinase receptor ex-
Shovlin et al. 1994); and HHT2, mapping to chromo-pressed predominantly in endothelial cells. The coding
some 12q13 (Johnson et al. 1995; Vincent et al. 1995).region is contained within nine exons, spanning õ15 kb
Patients with HHT linked to 9q33 may have a higherof genomic DNA. All introns follow the GT-AG rule,
incidence of symptomatic pulmonary arteriovenous mal-except for intron 6, which has a TAGÉgcaag 5 splice
formations than is seen in those with HHT linked tojunction. The positions of introns in the intracellular
12q13 (Heutink et al. 1994; McAllister et al. 1994b;domain are almost identical to those of the mouse serine-
Porteous et al. 1994; Berg et al. 1996), suggesting that,threonine kinase receptor TSK-7L. By sequencing ALK-
in the pulmonary vasculature, the HHT1 gene has an1 from genomic DNA, mutations were found in six of
additional role not shared by HHT2. A third rare variantsix families with HHT either shown to link to chromo-
of HHT has been reported in one large family withsome 12q13 or in which linkage of HHT to chromo-
hepatic involvement as the major manifestation (Pian-
some 9q33 had been excluded. Mutations were also
tanida et al. 1996), with exclusion of linkage to both
found in three of six patients from families in which chromosome 9 and chromosome 12.
available linkage data were insufﬁcient to allow cer- The genes involved at the two major loci have been
tainty with regard to the locus involved. The high rate of identiﬁed. HHT1 is the endoglin gene on chromosome
detection of mutations by genomic sequencing of ALK-1 9 (McAllister et al. 1994a); HHT2 is the ALK-1 gene
suggests that this will be a useful diagnostic test for on chromosome 12 (Johnson et al. 1996). Both of these
HHT2, particularly where preliminary linkage to chro- genes are members of the TGF-b receptor superfamily
mosome 12q13 can be established. In two cases in which (Cheifetz et al. 1992; Attisano et al. 1993; ten Dijke et
premature termination codons were found in genomic al. 1993). The ALK-1 protein has the properties of a
DNA, the mutant mRNA was either not present or pres- type I serine-threonine kinase receptor (Attisano et al.
ent at barely detectable levels. These data suggest that 1993; ten Dijke et al. 1993). It has been shown to bind
mutations in ALK-1 are functionally null alleles. either activin or TGF-b in the presence of their respective
type II receptors but does not bind ligand alone (Atti-
Introduction sano et al. 1993). The mechanism for downstream sig-
naling of ALK-1 has yet to be elucidated, but it seemsHereditary hemorrhagic telangiectasia (HHT) is an au-
probable that it involves pathways similar to those im-tosomal dominant disease of blood vessels that is charac-
plicated in the signaling of other serine-threonine kinase
receptors (Niehrs 1996; Zhang et al. 1996). Expression
studies of cell lines by reverse-transcriptase–PCR (RT-Received November 20, 1996; accepted for publication April 25,
1997. PCR) have shown that signiﬁcant transcription of ALK-
Address for correspondence and reprints: Dr. Douglas A. Marchuk, 1 occurs only in endothelial cell lines (Attisano et al.
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0002-9297/97/6101-0011$02.00 cyte mRNA. This has permitted identiﬁcation of three
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mutations in ALK-1 in unrelated individuals affected of the ALK-1 gene. Primer sequence and conditions are
given in table 1. PCR was carried out for 35 cycles: 95Cwith HHT2 (Johnson et al. 1996).
In this paper we have identiﬁed the size and position for 45 s, annealing temperature for 45 s, and 72C for
1 min. One hundred nanograms of each primer, 1 1of introns in the coding portion of the ALK-1 gene. We
have developed PCR assays to amplify each exon of the buffer, 50 ng of genomic DNA, 0.2 mM dNTPs, and 1
unit of Gibco-BRL Taq polymerase were used in eachcoding region of ALK-1, from genomic DNA. The ALK-
1 gene was sequenced in a panel of 12 unrelated patients 25-ml reaction. The buffer used was either that supplied
by Boehringer Mannheim Biochemicals (BMB) or thatwith HHT, 6 of whom have either evidence of HHT
linkage to markers on 12q13 or exclusion of linkage of originally used byWeissenbach (W; Gyapay et al. 1994);
in both cases the magnesium ion concentration was 1.5HHT to 9q34; for the remaining 6 insufﬁcient linkage
data were available. The position and type of each muta- mM.
tion found are discussed in relationship to both the func- Mutation Analysis
tion of the protein and the pathobiology of the disease.
For each patient in the study, each exon was ampliﬁed
and sequenced. Sequencing was performed by use ofSubjects, Material, and Methods
the Amersham Thermosequenase cycle sequencing kit,
Human Subjects which uses P33-labeled dideoxy terminators to reduce
Individuals with HHT had been assessed in, and DNA artifactual bands. Samples of each nucleotide-speciﬁc
samples had obtained from, families 1–5, 17, and 92, as termination reaction were loaded in adjacent lanes,
described elsewhere (McAllister et al. 1994b; Porteous et making a mutation in any single lane very easy to iden-
al. 1994; Johnson et al. 1995; Berg et al. 1996), after tify. In one instance, for family 92, it was necessary to
informed consent had been obtained. Single samples had clone the exon into PCR Script by using the Invitrogen
also been collected from four unrelated individuals by TA cloning kit, prior to sequencing. Conservation of the
use of the same methods. region affected by the mutation was determined by use
of the BLAST algorithm, to match the ALK-1 region
Identiﬁcation of a Genomic P1 Artiﬁcial Chromosome containing the mutation against the Genbank nonredun-
(PAC) Clone Containing ALK-1 dant protein database.
DNA from pools of a two-dimensional arrayed PAC
RT-PCRlibrary (Ioannou et al. 1994) was screened by use of the
For RT-PCR, peripheral blood leukocyte mRNA wasprimers 5-CGCGTGTCACACTTCATGGCTC-3 and
reverse transcribed by use of a mixture of oligo dT and5-ATCAGAAGGCCTTTCCTGGGGG-3, designed to
random hexamers. A 250-bp segment of ALK-1 exonthe 5 UTR of ALK-1 published by Attisano et al. (1993.
VII was ampliﬁed by use of primers 5-TGTGGCACG-The positive clone from a single positive 384-well plate
GTGAGAGTGTGGCC-3 and 5-GTTGCTCTTGAC-(plate 265) was identiﬁed at position C14 by hybridiza-
CAGCACAT-3. A minus-reverse-transcriptase controltion using standard protocols (Sambrook et al. 1989).
was included.This clone was designated ‘‘265C14.’’ Subclones were
generated by use of BglII-digested PAC cloned into Polymorphism Screen
BamHI-digested pBluescript phagemid (Stratagene). For each mutation, a panel of 100–120 normal indi-
viduals was screened to ensure that the mutation didLocalization of Introns
not arise as a population polymorphism. The screeningWith a range of primers designed from the published
was performed by altered restriction-enzyme site, wherecDNA sequence, PCR reactions were performed to am-
possible. In one case in which no enzyme site was al-plify segments of genomic DNA containing the ALK-1
tered, the mutant PCR product gave a heteroduplexgene. Whenever a PCR fragment generated was larger
band that could be resolved by gel electrophoresis asthan that predicted from the cDNA sequence, it was
described elsewhere (McAllister et al. 1995). For twoassumed to contain an intron and was sequenced. Where
mutations it was necessary to screen the population sam-sequencing was unclear, further sequence was generated
ples by sequencing the PCR product. In these instances,from the plasmid subclones by use of different primers
only a single termination reaction was run for each indi-designed for the ALK-1 cDNA sequence. Intron size was
vidual screened.estimated by size of PCR product, or, for three of the
introns, sequence was generated for the entire intron. Results
Genomic Structure of ALK-1PCR Ampliﬁcation of Individual Exons
A single PAC clone containing the ALK-1 gene wasWith the intronic sequence generated, primer pairs
were designed to amplify each exon of the coding part isolated from a human genomic PAC library (Ioannou
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Table 1
Primers for Ampliﬁcation of ALK-1 Gene Exons
Annealing
Temperature Size
Exon 5 Assay Primer 3 Assay Primer (C) Buffer (bp)
II CTCTGTGATTTCCTCTGGGCA TACATTCTCCCCAGCTTCTCAA 62a BMB 266
III AGCTGGGACCACAGTGGCTGA GGAGGCAGGGGCCAAGAAGAT 64 W 345
IV AGCTGACCTAGTGGAAGCTGA CTGATTCTGCAGTTCCTATCTG 60 W 318
V AGGAGCTTGCAGTGACCCAGCA ATGAGAGCCCTTGGTCCTCATCCA 68a BMB 242
VI AGGCAGCGCAGCATCAAGAT AAACTTGAGCCCTGAGTGCAG 60 BMB 294
VII TGACGACTCCAGCCTCCCTTAG CAAGCTCCGCCCACCTGTGAA 65a W 388
VIII AGGTTTGGGAGAGGGGCAGGAGT GGCTCCACAGGCTGATTCCCCTT 65 BMB 293
IX TCCTCTGGGTGGTATTGGGCCTC CAGAAATCCCAGCCGTGAGCCAC 68a BMB 256
X TCTCCTCTGCACCTCTCTCCCAA CTGCAGGCAGAAAGGAATCAGGTGCT 65a BMB 197
a Hot start improves ampliﬁcation.
et al. 1994). This PAC clone was designated ‘‘265C14.’’ The coding region of ALK-1 is contained within nine
exons. All except one intron follow the GT-AG rule.In Southern blot analysis, cDNA from the entire coding
region of ALK-1 hybridized to genomic fragments total- Intron 6, between exons VI and VII, has a nonconsensus
sequence at the 5 junction. The most likely position foring 15 kb. The position of each intron and the size of
each exon, as determined by PCR ampliﬁcation from the splice, however, gives the splice-junction sequence
TAGÉgcaag, which is the sequence most commonly re-the PAC clone, are shown in ﬁgure 1. Exon I contains
the 5 untranslated sequence published by ten Dijke et ported for nonimmunoglobulin eukaryotic nonconform-
ing 5 splice sites (Senapathy et al. 1990). The 3 spliceal. (1993) and was shown, by sequencing of a subclone,
to be present in 265C14. of this intron would then have the usual consensus se-
quence, cagÉG. Sequence data from all the intron-exonThe 5 untranslated sequence of ALK-1 differs in the
two published descriptions of this gene (Attisano et al. borders of the coding region are available as Genbank
accession numbers U77707–U77713.1993; ten Dijke et al. 1993). Genomic sequencing shows
that the 5 untranslated sequence published by Attisano
Comparison with a Murine Type I Kinaseis part of exon II. ten Dijke et al.’s version is a splice
variant arising from splicing of exon I to a consensus Another type I serine-threonine kinase receptor for
which the genomic structure has been published is thesplice junction present 7 bp upstream of the start codon
in exon II, where identity with Attisano et al.’s version mouse receptor TSK-7L (Ebner et al. 1993; Schmitt et
al. 1995), a homologue of human ALK-2 and activinof this sequence begins. This splice is marked with an
arrow in ﬁgure 1. A consensus splice is present at the type I receptor. The amino acid sequence of the kinase
domain is 79% identical to human ALK-1, but the extra-3 side of exon I. Both splice variants can be ampliﬁed
by RT-PCR of mRNA extracted either from endothelial cellular domain is only 23% identical. Comparison of
the intron-exon positions of ALK-1 with those of TSK-cell lines or from peripheral blood leukocytes.
Figure 1 Diagrammatic representation of the ALK-1 gene, approximately to scale. The exons are marked by boxes—unblackened for
the coding regions and black for the noncoding regions. The exon number referred to in the text is given as a roman numeral above the exon.
Exact exon size (in bp) is given below the exon, in arabic numerals. The curved arrow marks the putative alternative splice, in the 5 UTR,
that would lead to the 5 sequence published by ten Dijke et al. (1993). For the 5 Attisano et al. (1993) sequence, transcription would start
farther 5 in exon II.
/ 9a2d$$jy23 07-03-97 16:06:08 ajhgas UC-AJHG
63Berg et al.: ALK-1 Mutations in HHT Type 2
7L shows almost exact conservation of the position of mRNA. In two cases in which a premature termination
codon is created in exon VII by either a frameshift or aintrons within the kinase domain. It is notable that four
of the intron-exon splices occur between the ﬁrst and nonsense mutation, mRNAwas isolated from peripheral
blood leukocytes from an affected family member andsecond bases of a codon in the human sequence. Wher-
ever this happens, the amino acid involved is uncharged. was ampliﬁed by RT-PCR, by use of a single round
of PCR. In both cases, only the wild-type allele wasThis is also the case with the murine receptor. Although
the location of intron 6 is exactly conserved between represented at any appreciable level in the product.
These procedures were replicated, with the same result.mouse and human, the mouse intron follows the GT-AG
rule, whereas the human intron 6 has a nonconsensus Figure 3 shows this for a frameshift mutation in exon
VII, where no mutant transcript is visible.sequence, as outlined above.
Novel Mutations Detected in the ALK-1 Gene
Discussion
The entire coding portion and intron-exon borders of
the ALK-1 gene were sequenced in 12 unrelated individ- The position of introns within the kinase domain is
very highly conserved between mouse Tsk7L and humanuals affected with HHT. Mutations were found in ALK-
1 in nine of the patients. Of these, six were from families ALK-1. In both genes, four of the splice sites fall between
the ﬁrst and second bases of a codon that encodes ashowing either strong evidence of HHT linkage to chro-
mosome 12 (either a LOD score ú3.0, with closely neutral amino acid. It has been hypothesized that this
allows alternative splicing of the kinase domain, whichlinked markers, or a LOD score close to the maximum
predicted [in the previously published families 2, 3, and are still in frame but have variations in kinase activity
(Schmitt et al. 1995). Intron 6 of the ALK-1 gene has a17] or exclusion of chromosome 9 linkage with incon-
clusive evidence of linkage to chromosome 12 [in pre- variant splice sequence at the 5 side—AG/gcaag, in-
stead of the usual AG/gt. This has been observed in otherviously published families 4 and 5 and new family 92]).
Mutations were also found in three of six patients with genes (Senapathy et al. 1990). The 3 splice junction is
the usual consensus, cag/G. The function of this variantHHTwho were from small families for which there were
inclusive linkage data. For each mutation, 100–120 un- splice sequence is unknown, but it may represent a
means for controlling the amount of ALK-1 mRNA thatrelated individuals were analyzed, to show that the se-
quence change was a true mutation and not a population is spliced. This splice-sequence variation is not seen in
the mouse, but the splice location occurring between thepolymorphism. When other family members were avail-
able, the mutation was shown to be present in the other ﬁrst and second bases of a glycine codon is the same.
Mutations were found in ALK-1 in all three of theaffected individuals from the same kindred. The muta-
tions and their positions in the gene are described in families in which the disease is known to be linked to
the ALK-1 region, as well as in all three families in whichtable 2. Figure 2 shows sequence data and cosegregation
of the ALK-1 mutation with disease status in a part of linkage to HHT1 on chromosome 9 had been excluded.
When no linkage data were available, mutations werethe previously unpublished family 92.
For two of the three individuals for whom no muta- found in three of the six individuals analyzed. The three
patients in whom no mutation was found may cometion was found, a genomic Southern blot of DNA di-
gested with HindIII, EcoRI, or BglII and probed with from families in which the disease is linked to other loci,
or they may have a form of mutation not easily detectedALK-1 cDNA showed no evidence of a gross genomic
rearrangement. DNA available from the third individual by PCR and sequencing of the coding exons.
Genomic sequencing may prove a more reliable diag-was insufﬁcient for Southern blot analysis.
All 12 mutations seen so far (9 described here and 3 nostic test than RT-PCR from peripheral blood leuko-
cyte mRNA. A low level of the ALK-1 transcript indescribed elsewhere) leave the putative signal peptide
and the transmembrane domain of ALK-1 intact. Two leukocytes in addition to unstable mutant mRNA of
some mutations may lead to difﬁculties in detection ofmutations lead to the change of a conserved amino acid
in the extracellular domain. Two mutations would lead the mutation by RT-PCR. Our comparatively high rate
of mutation detection and the small size of the ALK-1to premature truncation of the ALK-1 protein just after
the transmembrane domain, if translated. The remaining gene make genomic sequencing a viable diagnostic test
for HHT2, particularly if a family has previously showneight mutations either change residues conserved in the
serine-threonine kinase family or lead to a frameshift linkage of the disease to chromosome 12q13. Since a
clinical diagnosis of HHT in young adults is often uncer-and premature stop in the kinase domain.
In order to determine whether a mutant protein is tain, presymptomatic diagnosis of HHT will allow
screening for the serious complications to be targetedrequired for the pathogenesis of the disease, we investi-
gated the presence of mutant transcripts in patient only to those at risk.
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Table 2
Summary of ALK-1 Mutations in HHT2
Exon Protein Region Mutation Found (Position) Effect on Protein
II Start None
Signal peptide
III Extracellular domain GrT (150) Trp (conserved)rCys
GrA (200) Arg (conserved)rGln
IV Extracellular domain GrA (423) Premature STOP (intracellular)
Transmembrane domain GrT (475) Premature STOP (intracellular)
Start of intracellular domain
V Glycine-Serine domain None
VI ATP binding site 3-bp deletion (694)a Deletion Ser in frame
Start of kinase domain
VII Kinase domain Ins T (865) Frame shift and premature STOP
CrA (924) Premature STOP
GrT (998) Ser (conserved)rIle
VIII Kinase domain CrT (1120) Arg (conserved)rTrp
TrG (1126)a Met (conserved)rArg
GrA (1232)a Arg (conserved)rGln
IX Kinase domain CrA (1270) Pro (conserved)rThr
X End of kinase domain None
a Previously published by Johnson et al. (1996).
All 12 mutations identiﬁed in ALK-1 leave the signal by point mutation in the kinase domain. This dominant-
negative effect is even more pronounced with truncatedpeptide and transmembrane domain intact. Two extra-
cellular mutations cause changes of conserved amino forms of the type II receptor.
However, RT-PCR of two premature protein-truncat-acids, and there are two premature stops before the gly-
cine-serine domain. The remaining mutations disrupt ing mutations observed in exon VII exhibit very low to
undetectable levels of the mutant transcript from cDNAthe kinase domain either by amino acid change or by
small insertion/deletion. Such mutations may function of peripheral blood leukocytes, suggesting that some
mutant transcripts are unstable. Vascular endothelialin one of several ways, including a dominant-negative
effect of the mutant ALK-1 receptor, haploinsufﬁciency cells from patients were unavailable for this expression
study. Nonetheless, these data suggest that a mutantof ALK-1 protein, or complete loss of functional ALK-
1 because of a second somatic mutation in the normal protein product may not be present for at least some
ALK-1 mutations and that a dominant-negative effect isallele.
The hypothesis of a dominant-negative effect requires not required for the pathogenesis of HHT.
The vascular lesions observed in HHT may developthat an altered protein be transcribed and translated
from the mutant allele—and that this protein interfere in response to reduced levels of ALK-1 that are due to
haploinsufﬁciency. The mutations identiﬁed to date arewith the function of the heteromeric receptor signaling
complex. Support for this mechanism includes the con- consistent with the hypothesis that they are all function-
ally null alleles. The inheritance of a single mutant copyservation of signal peptide and transmembrane regions
in all mutations found to date. If translated, the abnor- would then predispose the individual to develop the vas-
cular lesions observed in HHT. Lesion formation itselfmal ALK-1 protein may retain the ability to bind a type
II receptor in the presence of ligand; but it may not be could be due to local environmental or mechanical ef-
fects at the lumen of the vessel or to additional geneticable to transduce signal, either because of disruption of
the kinase domain or because of failure to bind ligand alterations.
Finally, it is possible that the development of a vascu-because of alteration of the extracellular domain. Simi-
lar mutations in another type I receptor show a domi- lar lesion initiates with a complete loss of ALK-1 signal-
ing in an endothelial cell. This could be due to somaticnant-negative effect. Wild-type Mv1Lu cells, which ex-
press the type I TGF-b receptor, show reduced TGF-b mutation of the normal ALK-1 allele. Some support for
the possibility of a ‘‘second hit’’ is given by the appar-signaling after transfection with an inactivated TGF-b
type I receptor (Feng et al. 1995; Yamamoto et al. 1996), ently random distribution of discrete lesions, the number
of which increases with age. Mucocutaneous telangiec-created either by deletion of the cytoplasmic domain or
/ 9a2d$$jy23 07-03-97 16:06:08 ajhgas UC-AJHG
65Berg et al.: ALK-1 Mutations in HHT Type 2
tases appear abruptly and are progressive (Plauchu et al.
1989). However, one study has shown that the classical
telangiectases arise as a result of dilatation of blood
vessels (Braverman et al. 1990) and do not appear to be
proliferative lesions. Also, studies on the development
and growth of pulmonary arteriovenous malformations
have shown gradual size increases with time, requiring
as long as a decade or more to double in diameter (Vase
et al. 1985; Masakazu et al. 1988). These studies suggest
that, if ALK-1 requires a somatic second mutation for
the formation of a vascular lesion, it is not acting as a
Figure 3 Unstable transcript of the mutant ALK-1 allele in fam-
ily 17. DNA and mRNA from peripheral blood leukocytes of an af-
fected individual (family 17) were used in genomic PCR and RT-PCR,
respectively. Both PCR products were then sequenced by use of an
identical primer within the exon. The sequence of the normal (N)
allele is apparent in both samples, whereas that of the mutant (M)
allele is seen only in the genomic PCR product. Insertion of a T (boxed
in the sequence at the left, indicated by an arrow to the right of
the band) produces, beyond the inserted nucleotide, superimposed
sequences of the normal and mutant alleles, only in the genomic prod-
uct.
tumor-suppressor gene. Since TGF-b signaling in endo-
thelial cells modulates vascular remodeling by inducing
changes in the extracellular matrix (Madri et al. 1989;
Merwin et al. 1990), complete loss of ALK-1 signaling
may induce remodeling of the vascular bed, rather than
directly affect the rate of endothelial cell proliferation.
The proof of this mechanism would require detection
of either loss of heterozygosity or somatic mutation of
the normal ALK-1 allele in the single layer of endothe-
lium removed from an HHT-associated vascular lesion.
In a similar analysis of the renal cysts seen in autosomal
dominant polycystic kidney disease type 1, loss of het-
erozygosity and somatic mutation of the normal PKD1
Figure 2 Molecular analysis of the ALK-1 mutation in family allele were observed only when methods were developed
92. a, Portion showing affected family members. The disease status to isolate the single layer of epithelium lining the renal
cosegregates with presence of a StuI site in the exon VII product shown cysts (Qian et al. 1996).in panel b. b, StuI digest of the exon VII PCR product from family
92. The mutation creates a site that leads to generation of fragments
of Ç170 and Ç210 bp, as well as to an undigested fragment of 380
Acknowledgmentsbp. In unaffected individuals, only the undigested fragment is seen. A
100-bp ladder is used as the size standard. c, Sequence from an affected
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product. the rate of growth of pulmonary arteriovenous malformations.
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